Torrent Pharmaceuticals Limited has received a corrigendum order from the National Company Law Tribunal (NCLT) Ahmedabad Bench and has now scheduled an equity shareholders meeting to consider the proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited. The company filed official communications on March 28, 2026, announcing the NCLT-directed meeting scheduled for April 28, 2026.

NCLT Order and Meeting Schedule

Following the NCLT Ahmedabad Bench order dated March 23, 2026, and subsequent corrigendum order dated March 24, 2026, Torrent Pharmaceuticals has scheduled a crucial shareholders meeting. The meeting will be conducted through video conferencing/other audio-visual means on Tuesday, April 28, 2026, at 10:00 a.m. (IST).

Remote E-Voting Schedule

Equity shareholders will have the opportunity to participate through remote e-voting facility prior to the meeting. The company has established a comprehensive voting timeline to ensure maximum participation in the amalgamation approval process.

Official Communications and Compliance

Torrent Pharmaceuticals filed intimations with both BSE Limited and National Stock Exchange of India Limited on March 28, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Chintan M. Trivedi, Company Secretary, and included newspaper publication details in Indian Express (English) and Sandesh (Gujarati) editions.

Amalgamation Structure and Tribunal Appointments

Under the proposed Scheme of Amalgamation, J.B. Chemicals & Pharmaceuticals Limited will serve as the transferor company, while Torrent Pharmaceuticals Limited will act as the transferee company. The NCLT has appointed key officials to oversee the meeting proceedings, ensuring proper governance and compliance.

Shareholder Participation Guidelines

Shareholders whose names appear in the register of members or beneficial owners as on the cut-off date will be entitled to vote on the amalgamation proposal. The company has made arrangements for both physical and electronic copies of meeting notices, with detailed instructions available on the company website and stock exchange platforms. Physical attendance has been dispensed with due to the video conferencing format, and proxy appointments are not available for this meeting.

Morgan Stanley has initiated coverage on Torrent Pharmaceuticals with an Equal Weight rating, setting a target price of Rs 4,580. The global investment bank's analysis highlights both growth opportunities and near-term challenges for the pharmaceutical company.

Market Position and Growth Drivers

The brokerage firm emphasizes Torrent Pharmaceuticals' robust position in the Indian Pharmaceutical Market (IPM), particularly noting its strong chronic-led presence with approximately 5% market share. This established market position forms a key foundation for the company's growth prospects.

Integration Benefits and Cost Synergies

Morgan Stanley projects significant cost synergies ranging from ₹3 billion to ₹4.5 billion following integration activities. These synergies are expected to provide substantial support for the company's medium-term growth trajectory, contributing to operational efficiency improvements and enhanced profitability.

FY27 Outlook and Valuation Concerns

Despite the positive medium-term outlook, Morgan Stanley characterizes FY27 as a transition year for Torrent Pharmaceuticals. The brokerage notes that the stock has experienced recent re-rating, which limits the potential for significant upside in the near term. This assessment contributes to the Equal Weight rating, suggesting the stock is fairly valued at current levels.

The initiation of coverage with an Equal Weight rating reflects Morgan Stanley's balanced view of Torrent Pharmaceuticals' prospects, acknowledging both the company's strong market fundamentals and the current valuation constraints.